AstraZeneca Aktie
| 121,40EUR | 1,05EUR | 0,87% |
WKN: 886455 / ISIN: GB0009895292
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 94,72 |
| Government Pension Fund - Global (The) | 2,35 |
| Vanguard Total International Stock Index Fund | 1,35 |
| Vanguard Health Care Fund | 1,12 |
| American Funds New Perspective Fund | 0,99 |
| Goldman Sachs GQG Partners International Opportunities Fund | 0,95 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 70 600 | 76 100 | 83 100 | 83 500 | 89 900 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,27 | 0,28 | 0,33 | 0,43 | 0,41 |
Bilanz (in Mio. GBP) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 11 748 | 14 298 | 19 376 | 18 782 | 19 653 |
| Summe Anlagevermögen | 34 583 | 34 518 | 58 414 | 61 427 | 59 668 |
| Summe Aktiva | 46 331 | 48 816 | 77 790 | 80 209 | 79 321 |
Bilanz (in Mio. GBP) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 13 759 | 14 909 | 22 726 | 24 301 | 22 452 |
| Summe Fremdkapital | 35 313 | 37 376 | 48 784 | 49 401 | 48 598 |
| Summe Eigenkapital | 11 018 | 11 440 | 29 006 | 30 807 | 30 723 |
| Summe Passiva | 46 331 | 48 816 | 77 790 | 80 209 | 79 321 |
Adresse
| Cambridge Biomedical Campus, CB2 0AA Cambridge | |
| Telefon | +44 (20) 3749-5000 |
| Internet | http://www.astrazeneca.co.uk |
Management
|
Adrian Charles Noel Kemp
Secretary |
|
Alberto Hegewisch
Chief Medical Officer |
|
Andreas Rummelt
Non-Executive Director |
|
Anna Olive Magdelene Manz
Non-Executive Director |
|
Aradhana Sarin
Chief Financial Officer & Executive Director |
|
Cindy L. Hoots
Chief Digital & Information Officer |
|
David Fredrickson
Executive Vice President-Oncology Business Unit |
|
Deborah DiSanzo
Independent Non-Executive Director |
|
Diana Layfield
Non-Executive Director |
|
Euan A. Ashley
Non-Executive Director |
|
Helen MacPhee
Vice President |
|
Iskra Reic
EVP-Vaccines & Immune Therapies |
|
Jeffrey Pott
CHRO, Chief Compliance Officer & General Counsel |
|
Jonathan Thomas Charles Slade
Group Treasurer |
|
Kevin G. Lokay
Head-Change Implementation |
|
Marc Pierre Jean Dunoyer
Chief Strategy Officer |
|
Marcus Wallenberg
Independent Non-Executive Director |
|
Margareta Elisabeth Björk
Senior VP & Head-Late-stage Development |
|
Michel Demaré
Chairman |
|
Nazneen Rahman
Independent Non-Executive Director |
|
Pam P. Cheng
Executive VP-Operations & Information Technology |
|
Pascal Soriot
Chief Executive Officer & Executive Director |
|
Philip Arthur John Broadley
Senior Independent Non-Executive Director |
|
Regina Fritsche-Danielson
SVP, Head-Research & Early Development |
|
Ruud Dobber
Executive VP-Biopharmaceuticals Business |
|
Sharon Barr
EVP-BioPharmaceuticals Research & Development |
|
Sherilyn D. McCoy
Independent Non-Executive Director |
|
Shu Kam Mok
Independent Non-Executive Director |
|
Sjoerd Hubben
Vice President-Global Government Affairs & Policy |
|
Susan Mary Galbraith
Executive VP-Oncology Research & Development |
|
Tyrell J. Rivers
Executive Director-Corporate Development |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
